ArticleFrontiers in immunology2026
Durable immunovirological control after sequential mogamulizumab and tucidinostat in relapsed or refractory adult T-cell leukemia/lymphoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive HTLV-1-associated T-cell neoplasm, and durable control of relapsed/refractory disease remains difficult without allogeneic hematopoietic stem cell transplantation. Mogamulizumab, an afucosylated anti-C-C chemokine receptor type 4 (CCR4) monoclonal antibody, and tucidinostat, an oral histone deacetylase inhibitor, have activity in this setting, but the immunovirological consequences of sequential CCR4-directed therapy and epigenetic modulation are unclear. We describe two patients with relapsed or refractory ATLL who achieved prolonged disease control after mogamulizumab/tucidinostat-based sequential therapy and underwent longitudinal monitoring of Tax301-309-specific CD8+ T cells, CD4/CD8 dynamics, HTLV-1 proviral DNA, and T-cell receptor (TCR) Vβ repertoire. Patient 1 had lymphoma-type ATLL with metabolic partial response after mogamulizumab plus EPOCH; tucidinostat was initiated 63 days after the final mogamulizumab dose. Tax301-309-specific CD8+ T cells increased from 0.03% at tucidinostat initiation to >0.8% during long-term follow-up, and disease control persisted for 32 months after tucidinostat initiation. Patient 2 had multiply relapsed ATLL and received four cycles of sequential mogamulizumab/tucidinostat, followed by rapid disappearance of circulating ATLL cells, normalization of soluble interleukin-2 receptor, and marked reduction of HTLV-1 proviral load from 565.7 copies/1,000 peripheral blood mononuclear cells to low levels. Disease control persisted for 17 months after treatment discontinuation. In both patients, TCR Vβ repertoire analysis showed memory CD8+ T-cell-predominant patterns, including expansion of a Vβ2 memory CD8+ T-cell population. These observations are hypothesis-generating and suggest that sequential tumor debulking, CCR4/Treg-axis modulation, and epigenetic treatment may create a context permissive for HTLV-1 antigen-specific cellular immune surveillance in selected patients with ATLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.